XOMA · Insider Trading
XOMA Royalty Corporation Common Stock
Every open-market purchase and sale reported by XOMA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-16 | BVF II GP LLC | 10%+ Owner | U | −7,593,303 | — |
| 2026-07-14 | Jeffrey Trigilio | Chief Financial Officer | J | −103,906 | — |
| 2026-07-14 | Maricel Perea Montano | Chief Legal Officer | J | −42,371 | — |
| 2026-07-14 | Owen Hughes | Chief Executive Officer | MIXED | −294,016 | — |
| 2026-07-14 | Heather L Franklin | Director | J | −6,269 | — |
| 2026-07-14 | Natasha Hernday | Director | MIXED | −13,304 | — |
| 2026-07-14 | Bradley Sitko | Chief Investment Officer | MIXED | −96,067 | — |
| 2026-07-14 | Joseph M Limber | Director | MIXED | −39,532 | — |
| 2026-07-14 | Barbara Kosacz | Director | J | −6,269 | — |
| 2026-07-14 | Jack L Wyszomierski | Director | J | −21,828 | — |
| 2026-07-14 | Matthew D Perry | Director | J | −24,138 | — |
| 2020-12-15 | Matthew D Perry | Director | Buy | +200,000 | +$5.00M |
| 2020-12-15 | BVF GP HOLDINGS LLC | 10%+ Owner | Buy | +200,000 | +$5.00M |
| 2020-11-24 | Thomas M. Burns | SVP, Finance & CFO | MIXED | — | −$343.95K |
| 2020-11-24 | James R Neal | CEO | MIXED | — | −$546.18K |
| 2020-11-06 | Thomas M. Burns | SVP, Finance & CFO | MIXED | — | −$176.67K |
| 2020-11-06 | James R Neal | CEO | MIXED | — | −$205.20K |
| 2020-09-23 | BIOTECHNOLOGY VALUE FUND L P | 10%+ Owner | Buy | +51,368 | +$941.96K |
| 2020-09-10 | Biotechnology Value Trading Fund OS LP | — | Buy | +7,737 | +$145.23K |
| 2020-09-01 | BIOTECHNOLOGY VALUE FUND II LP | 10%+ Owner | Buy | +35,621 | +$666.48K |
| 2020-08-25 | BVF Partners OS Ltd. | — | Buy | +28,175 | +$546.65K |
| 2020-08-20 | BVF PARTNERS L P/IL | 10%+ Owner | Buy | +6,163 | +$120.00K |
| 2020-08-14 | BVF GP HOLDINGS LLC | 10%+ Owner | Buy | +27,022 | +$498.74K |
| 2020-07-02 | Natasha Hernday | Director | A | +13,251 deriv. | — |
| 2020-05-27 | Jack L Wyszomierski | Director | A | +6,152 deriv. | — |
| 2020-05-27 | Matthew D Perry | Director | A | — | — |
| 2020-05-27 | Barbara Kosacz | Director | A | +6,152 deriv. | — |
| 2020-05-27 | Joseph M Limber | Director | A | +6,152 deriv. | — |
| 2020-05-27 | W Denman Van Ness | Director | A | +6,152 deriv. | — |
| 2020-04-17 | Biotechnology Value Trading Fund OS LP | — | C | +1,252,772 | +$16.29M |
| 2020-03-27 | BVF II GP LLC | 10%+ Owner | Buy | +8,264 | +$142.13K |
| 2020-03-24 | James R Neal | CEO | Buy | +1,000 | +$14.50K |
| 2020-03-23 | James R Neal | CEO | Buy | +1,000 | +$16.41K |
| 2020-03-20 | BIOTECHNOLOGY VALUE FUND II LP | 10%+ Owner | Buy | +4,439 | +$64.47K |
| 2020-03-17 | BVF I GP LLC | 10%+ Owner | Buy | +118,277 | +$2.12M |
| 2020-03-16 | Thomas M. Burns | SVP, Finance & CFO | A | +22,000 deriv. | — |
| 2020-03-16 | James R Neal | CEO | A | +66,200 deriv. | — |
| 2020-01-16 | James R Neal | CEO | X | +1,180 | +$25.96K |
| 2019-12-20 | Mark N Lampert | 10%+ Owner | MIXED | +845,463 | +$18.60M |
| 2019-11-08 | James R Neal | CEO | MIXED | — | −$71.74K |
| 2019-09-20 | James R Neal | Chief Executive Officer | MIXED | — | −$242.84K |
| 2019-09-20 | Thomas M. Burns | Sr. VP, Finance and CFO | MIXED | — | −$141.15K |
| 2019-05-20 | Jack L Wyszomierski | Director | A | +8,167 deriv. | — |
| 2019-05-20 | Joseph M Limber | Director | A | +8,167 deriv. | — |
| 2019-05-20 | Barbara Kosacz | Director | A | +8,167 deriv. | — |
| 2019-05-20 | Matthew D Perry | Director | A | — | — |
| 2019-05-20 | W Denman Van Ness | Director | A | +8,167 deriv. | — |
| 2019-05-14 | W Denman Van Ness | Director | Sell | −130 | −$1.91K |
| 2019-05-14 | Biotechnology Value Trading Fund OS LP | — | Buy | +27,913 | +$408.23K |
| 2019-02-15 | Deepshikha Datta | Chief Business Officer | A | +50,000 deriv. | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the XOMA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.